Dry Eye Syndrome Clinical Trial
NCT number | NCT02455999 |
Other study ID # | SYL1001_III |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | May 20, 2015 |
Last updated | April 4, 2016 |
Start date | June 2015 |
The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001 eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.
Status | Completed |
Enrollment | 66 |
Est. completion date | |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Give written informed consent to participate in the study, after having received all information relating to the design, aims and possible risks resulting therefrom. - Common symptoms of persistent, daily, mild to moderate dry eye lasting more than three months: OSDI scale between 13-70 and VAS scale between 2 -7. - Eye tests in both eyes: Corneal fluorescein staining (Oxford scale > 0), Tear break-up time < 10 seconds and Schirmer's test with anaesthesia < 10 mm/5min. Exclusion criteria: - Women who are pregnant or breastfeeding or who have a positive urine pregnancy test. Women who do not commit to use a medically acceptable method of contraception from the time of selection and throughout the study. - Any current, relevant disease, including respiratory disease, cardiovascular disease, endocrine disease, neurological disease, haematological disease, kidney disease, oncological disease, liver disease, gastrointestinal dysfunction, hypertension or active acute infectious processes. - Previous chronic or recurrent processes which, according to the investigator, could affect the development of the study. - Concomitant use of other medications with analgesic activity by any route of administration at the time of entry into the study. - Change in any concomitant eye and/or systemic medication of the patient one month before the study and during the study. - Changes in the pre-established administration schedule of artificial tears during the 15 days before the study and during the 10 days of the study. - Initiation of treatment with cyclosporine or changes in the dosage or administration schedule of cyclosporine within the 6 months before inclusion in the study. - History of hypersensitivity to drugs. - Use of contact lenses during the treatment and previous 15 days. - History of drug abuse or drug or alcohol dependence. - Laboratory abnormalities which, in the investigator's opinion, are clinically significant. - Previous refractive surgery. - Having participated in another clinical trial within the 2 months prior to inclusion. - Another eye disease that is significant in the investigator's opinion. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Estonia | East Tallinn Central Hospital | Tallinn | |
Estonia | Eye Clinic Dr. Krista Turman | Tallinn | |
Spain | Fundación Jiménez Díaz | Madrid | |
Spain | Hospital U. Clínico San Carlos | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Clínica Universidad de Navarra | Pamplona |
Lead Sponsor | Collaborator |
---|---|
Sylentis, S.A. |
Estonia, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from the baseline scoring of eye pain on the Visual Analogue Scale (VAS) | 10 consecutive days | No | |
Primary | Change from the baseline scoring of ocular discomfort in the Ocular Surface Disease Index (OSDI) | 10 consecutive days | No | |
Primary | Change from the baseline scoring after fluorescein staining of the cornea | 10 consecutive days | Yes | |
Primary | Frequency of occurrence of conjunctival hyperaemia | 10 consecutive days | Yes | |
Secondary | Change from baseline in vital signs | 10 consecutive days | Yes | |
Secondary | Change from baseline in standard laboratory parameters | 10 consecutive days | Yes | |
Secondary | Assessment of Adverse Events (AEs) as a measure of SYL1001 safety | 20 consecutive days | Yes | |
Secondary | Change from baseline in standard ocular parameters | 10 consecutive days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02597803 -
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
|
Phase 2/Phase 3 | |
Completed |
NCT02522312 -
A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
|
N/A | |
Completed |
NCT01863368 -
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
|
N/A | |
Completed |
NCT01753752 -
Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation
|
Phase 2 | |
Completed |
NCT01753687 -
Correlation of Different Signs for Assessment of Dry Eye Syndrome
|
N/A | |
Completed |
NCT01198782 -
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
|
Phase 4 | |
Completed |
NCT01212471 -
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
|
Phase 3 | |
Completed |
NCT01162954 -
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00535054 -
Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms
|
N/A | |
Completed |
NCT00544713 -
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery
|
N/A | |
Completed |
NCT00344721 -
A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
|
N/A | |
Completed |
NCT03830359 -
Efficacy, Safety of T2769 in Dry Eye Disease
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02758327 -
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
|
Phase 4 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Completed |
NCT01970917 -
Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects
|
Phase 4 | |
Completed |
NCT02092207 -
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01541891 -
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01252121 -
Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline
|
N/A | |
Completed |
NCT00765804 -
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
|
Phase 2 |